Vertex insider plans sale of 2,437 shares

Vertex Pharmaceuticals (VRTX) insider Mark Bunnage filed a notice to sell 2,437 shares of Vertex common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,192,814.02, with an approximate sale date of February 17, 2026.

Rhea-AI Filing Summary

Vertex Pharmaceuticals (VRTX) insider Mark Bunnage filed a notice to sell 2,437 shares of Vertex common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,192,814.02, with an approximate sale date of February 17, 2026.

The shares to be sold were acquired on February 13, 2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Bunnage sold 2,021 Vertex common shares on February 11, 2026 for gross proceeds of $930,529.03 and 23 shares on December 29, 2025 for $10,649.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Vertex (VRTX) Form 144 filing by Mark Bunnage disclose?

The filing discloses a planned sale of Vertex (VRTX) common stock by Mark Bunnage. It covers 2,437 shares to be sold on NASDAQ through Fidelity, with an aggregate market value of $1,192,814.02, under Rule 144 resale provisions.

How many Vertex (VRTX) shares are covered by this Form 144 and what is their value?

The notice covers 2,437 Vertex common shares proposed for sale. The aggregate market value reported for these shares is $1,192,814.02, with the sale expected to occur on or around February 17, 2026 on the NASDAQ exchange.

How did Mark Bunnage acquire the Vertex (VRTX) shares now being sold?

The 2,437 Vertex (VRTX) shares were acquired on February 13, 2026 via restricted stock vesting from the issuer. The filing states the nature of payment as compensation, indicating these were part of an equity compensation award rather than an open-market purchase.

What recent Vertex (VRTX) stock sales by Mark Bunnage are disclosed?

The filing reports two prior Vertex (VRTX) stock sales in the past three months. On February 11, 2026, 2,021 common shares were sold for gross proceeds of $930,529.03. On December 29, 2025, 23 common shares were sold for $10,649.00.

Which broker and exchange are involved in the planned Vertex (VRTX) share sale?

The planned sale of Vertex (VRTX) shares is to be executed through Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island. The filing lists the intended trading venue as the NASDAQ stock exchange for the 2,437 common shares.

What representation does the seller make in the Vertex (VRTX) Form 144 notice?

By signing the notice, the seller represents they do not know any material adverse information about Vertex’s current or prospective operations that has not been publicly disclosed, consistent with the representations required when relying on Rule 144 resale provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 03:26 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002100735
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Bunnage Mark E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2437	1192814.02	254034190	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/13/2026	Restricted Stock Vesting	Issuer			2437	02/13/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Bunnage 50 Northern Avenue Boston MA 02210	Common	02/11/2026	2021	930529.03
Mark Bunnage 50 Northern Avenue Boston MA 02210	Common	12/29/2025	23	10649.00

144: Remarks and Signature

Remarks
Date of Notice	02/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Mark E. Bunnage
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)